Main Article Content
Objective: To study the efficacy, safety, patient satisfaction, discontinuation and need for hysterectomy in patients using Mirena LNG-IUS as treatment of HMB.
Material & Methods: This study was conducted at the department of Gynecology & Obstetrics, Ayub Teaching Hospital from January 2016 to August 2021. All women who opted for Mirena LNG IUS as treatment of heavy menstrual bleeding, or already using Mirena during the study period were included. Data was collected on a structured pro forma and patients were followed initially for one year and then for five years of use of Mirena or till expulsion or discontinuation of use. A total of 88 women with heavy menstrual bleeding who had been inserted MIRENA LNG-IUS were enrolled in the study.
Results: Overall 88.1% of Mirena users reported improvement in HMB. Of these, about 36.4% of study participants reported improved menstrual flow during next menstrual cycle, 52.4% had improved / normal menstrual flow within 6 months of Mirena LNG-IUS use, while 7% had their Mirena LNG-IUS removed early due to side effects and only 4.54% failed to respond to Mirena LNG-IUS. Reported common side effects included spotting (25%), Amenorrhea (6%), oligomenorrhea (42%), weight gain (14%), breast pain and heaviness (7%), mood changes not including depression (7%) and depression (7%).
Conclusion: Mirena LNG-IUS is an effective, cost-saving non-surgical treatment option for women with heavy menstrual bleeding and should be offered as a preferred treatment option to such women